Yahoo Web Search

Search results

1. • Undervalued

     • Is Heron Therapeutics overvalued? According to Wall Street analysts Heron Therapeutics’s price is currently Undervalued.
     www.tipranks.com/stocks/hrtx

     Heron Therapeutics (HRTX) Stock Price & Analysis - TipRanks

2. People also ask

   Is Heron Therapeutics (hrtx) undervalued?

   • The company underwent a leadership change and implemented a plan to improve efficiency and profitability. Zynrelef, an opioid alternative, has the potential to become one of Heron Therapeutics' main value drivers. From a multiples-based valuation perspective, HRTX looks decidedly undervalued.

   Why Heron Therapeutics Is A Compelling Buy Into 2024 - Seeking Alpha

   seekingalpha.com/article/4655013-why-heron-therapeutics-is-a-compelling-buy-into-2024

   See all results for this question

   What is the 12-month price forecast for heron Therapeutics (hrtx)?

   • The 12-month stock price forecast is $6.0, which is an increase of 226.09% from the latest price. SAN DIEGO , Oct. 10, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today reaffirmed the Company's ability to supply...

   Heron Therapeutics, Inc. (HRTX) Stock Price, Quote & News - Stock Anal…

   stockanalysis.com/stocks/hrtx/

   See all results for this question

   Should you buy hrtx (hrtx) stock?

   • Losses were -$110.56 million, -39.26% less than in 2022. According to 3 analysts, the average rating for HRTX stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 226.09% from the latest price.

   Heron Therapeutics, Inc. (HRTX) Stock Price, Quote & News - Stock Anal…

   stockanalysis.com/stocks/hrtx/

   See all results for this question

   Is hrtx (hrtx) undervalued?

   • The company also has $77.4 million in cash, $180.0 million of total debt, and a $205.60 million market cap, resulting in an enterprise value of $308.2 million. Hence, this implies an EV/Sales ratio of 2.47, well below the sector's EV/Sales ratio of 3.24. This suggests that HRTX is likely undervalued to some extent at its current price tag.

   Why Heron Therapeutics Is A Compelling Buy Into 2024 - Seeking Alpha

   seekingalpha.com/article/4655013-why-heron-therapeutics-is-a-compelling-buy-into-2024

   See all results for this question

   Should you buy zynrelef (hrtx)?

   • Zynrelef, an opioid alternative, has the potential to become one of Heron Therapeutics' main value drivers. From a multiples-based valuation perspective, HRTX looks decidedly undervalued. I posit it has up to a 47.1% upside potential with a $2.02 price target.

   Why Heron Therapeutics Is A Compelling Buy Into 2024 - Seeking Alpha

   seekingalpha.com/article/4655013-why-heron-therapeutics-is-a-compelling-buy-into-2024

   See all results for this question

   Who is Heron Therapeutics?

   • Heron Therapeutics is a commercial-stage biotechnology company based in San Diego, CA. It was founded in February 1983 and was initially known as A.P. Pharma, Inc., before it changed its name to Heron Therapeutics, Inc. in January 2014. HRTX develops agents to alleviate pain and discomfort produced by chemotherapy or surgery.

   Why Heron Therapeutics Is A Compelling Buy Into 2024 - Seeking Alpha

   seekingalpha.com/article/4655013-why-heron-therapeutics-is-a-compelling-buy-into-2024

   See all results for this question

3. simplywall.st › heron-therapeutics › valuationHeron Therapeutics (NasdaqCM:HRTX) Stock Valuation, Peer ...

   simplywall.st › heron-therapeutics › valuation

   • Cached

   Potentially undervalued companies in the Pharmaceuticals-biotech industry. Research Heron Therapeutics' (Nasdaq:HRTX) stock key valuation metrics while comparing it with its industry peers & market side by side.

4. seekingalpha.com › article › 4655013-why-heronWhy Heron Therapeutics Is A Compelling Buy Into 2024

   seekingalpha.com › article › 4655013-why-heron

   Nov 30, 2023 · Zynrelef, an opioid alternative, has the potential to become one of Heron Therapeutics' main value drivers. From a multiples-based valuation perspective, HRTX looks decidedly undervalued.

5. www.tipranks.com › stocks › hrtxHeron Therapeutics (HRTX) Stock Price & Analysis - TipRanks

   www.tipranks.com › stocks › hrtx

   According to Wall Street analysts Heron Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium Does Heron Therapeutics pay dividends?

   • 3.5/5 (8)

6. stockanalysis.com › stocks › hrtxHeron Therapeutics, Inc. (HRTX) Statistics & Valuation ...

   stockanalysis.com › stocks › hrtx

   • Cached

   3 days ago · The average price target for HRTX is $6.00, which is 233.33% higher than the current price. The consensus rating is "Strong Buy".

7. stockanalysis.com › stocks › hrtxHeron Therapeutics, Inc. (HRTX) - Stock Analysis

   stockanalysis.com › stocks › hrtx

   • Cached

   Oct 25, 2024 · Get a real-time Heron Therapeutics, Inc. (HRTX) stock price quote with breaking news, financials, statistics, charts and more.

   • Market Cap: 274.52M
   • Revenue (ttm): 136.36M

   • Net Income (ttm): 48.13M
   • Shares Out: 151.67M

   • 
   • 
   • 
   • 

8. www.fool.com › quote › nasdaqHeron Therapeutics (NASDAQ: HRTX) - The Motley Fool

   www.fool.com › quote › nasdaq

   • Cached

   Real time Heron Therapeutics (HRTX) stock price quote, stock graph, news & analysis.

9. uk.finance.yahoo.com › quote › HRTXHeron Therapeutics, Inc. (HRTX) - Yahoo Finance

   uk.finance.yahoo.com › quote › HRTX

   • Cached

   Find the latest Heron Therapeutics, Inc. (HRTX) stock quote, history, news and other vital information to help you with your stock trading and investing.